Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)‑positive advanced salivary duct carcinoma: A case report

Gibo, Takahiko; Sekiguchi, Nodoka; Gomi, Daisuke; Noguchi, Takuro; Fukushima, Toshirou; Kobayashi, Takashi; Ozawa, Takesumi; Yamada, Shin‐ichi; Koizumi, Tomonobu

doi:10.3892/mco.2019.1875

Cited by 10 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In case reports, a total of twelve patients received a combination of trastuzumab with docetaxel/paclitaxel [22][23][24]27,30,34,38,48,56]. Two patients had CR (17%) and eight patients had PR (67%).…”

Section: Her2 Targeted Therapymentioning

confidence: 99%

See 1 more Smart Citation

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review

Uijen¹,

Lassche²,

Grunsven³

et al. 2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

Background: Salivary duct carcinoma (SDC) is an aggressive subtype of salivary gland cancer. Approximately half of SDC patients will develop recurrences or metastases. Therapeutic palliative therapy is therefore often needed. The majority of SDC tumors expresses the androgen receptor (AR) and one-third expresses human epidermal growth factor receptor 2 (HER2), both are potential therapeutic targets. The aim of this paper is to systematically review and summarize the evidence on systemic palliative therapy for SDC and to provide treatment recommendations. Materials and methods: Electronic libraries were systematically searched with a broad search strategy to identify studies where SDC patients received systemic therapy. Due to the rarity of SDC no restrictions were placed on study designs. Results: The search resulted in 2014 articles of which 153 were full-text analyzed. Forty-five studies were included in the analysis, which included in total 256 SDC patients receiving systemic therapy. Two phase 2 trials primarily including SDC patients were identified. The majority of the studies were case series or case reports, resulting in an overall low quality of available evidence. Based on studies including ≥ 5 SDC patients, objective responses to HER2 targeting agents were observed in 60-70%, to AR pathway agents in 18-53% and to chemotherapy in 10-50%. Conclusion: For AR or HER2 positive SDC, agents targeting these pathways are the cornerstone for palliative treatment. Regarding chemotherapy, the combination of carboplatin combined with a taxane is best studied. Regarding other targeted agents and immunotherapy evidence is anecdotal, limiting formulation of treatment recommendations for these antineoplastic agents.

show abstract

Section: Her2 Targeted Therapymentioning

confidence: 99%

“…Additional SDC case reports mentioned the effect of different combinations of chemotherapy in seven patients [24,30,43,48,61]. Three out of these seven patients had PR (one on CAP, one with cisplatin + vinorelbine, one with cisplatin + docetaxel).…”

Section: Chemotherapymentioning

confidence: 99%

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review

Uijen¹,

Lassche²,

Grunsven³

et al. 2020

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

“…Human epidermal growth factor receptor 2 is a member of the human epidermal growth factor receptor family and is associated with a poor prognosis in breast carcinomas. 20,21 Overexpression of HER2 is also common in salivary gland cancers and is generally associated with a poor prognosis and aggressive tumor behavior. 22,23 In our study, HER2 was found to be positive in 28% of the patients with malignant SGTs, but there was no correlation between HER2 expression and RANK and RANKL expression.…”

Section: Discussionmentioning

confidence: 99%

RANK and RANKL Expression in Salivary Gland Tumors

Aslan

Küçük

2020

Ear Nose Throat J

View full text Add to dashboard Cite

Objectives: The pathogenesis and molecular basis of salivary gland tumors (SGT) are not well understood. We investigated the expression of receptor activator of nuclear factor κB (RANK) and RANK ligand (RANKL) in benign and malignant SGTs and their relationship with clinicopathological features. Methods: Fifty malignant and 38 benign SGTs were analyzed in this study. We evaluated the correlation between RANK and RANKL expression and benign and malignant tumors, as well as the correlation between clinicopathological prognostic parameters and RANK and RANKL expression. Results: Receptor activator of nuclear factor κB was positive in 82% (41) malignant SGTs and in 34.2% (13) benign SGTs. Receptor activator of nuclear factor κB ligand was expressed in 28% (14) malignant and 5.3% (2) benign tumors. Receptor activator of nuclear factor κB and RANKL expression were significantly different between benign and malignant SGTs ( P < .001, P = .006, respectively). However, a relationship was not found between positive expression of RANK or RANKL and clinicopathological features. Conclusions: In our study, RANK and RANKL expression was found to be higher in malignant SGTs compared to benign SGTs and RANK was more sensitive than RANKL. In addition, RANK and RANKL expression was higher in some malignant histological subtypes. Based on these results, we think that RANK and RANKL expression in SGTs and its potential as a target for treatment should continue to be investigated.

show abstract

“…Currently, more information is gathered about possible molecular targets for a tailored therapy for SGCs [19,20]. Promising results have been achieved with, for example, Herceptin and NTRK inhibitors in selected patients with primarily unresectable disease [10,21,22].…”

Section: Introductionmentioning

confidence: 99%

Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target

Wolber

Nachtsheim

Hoffmann

et al. 2021

Head and Neck Pathol

View full text Add to dashboard Cite

Treatment options for unresectable, recurrent or metastatic salivary gland carcinomas (SGC) are scarce. Trophoblast cell surface antigen 2 (Trop-2) is a transmembrane glycoprotein that is involved in a variety of oncogenic cell signaling pathways. Its potential as a target for the antibody–drug conjugate sacituzumab govitecan has already been demonstrated in different tumor entities. The United States Food and Drug Administration approved this antibody–drug conjugate for the treatment of metastatic triple-negative breast cancer. Here, we aimed to investigate Trop-2 protein expression in different entities of SGCs. We retrospectively reviewed the medical records of all patients that underwent surgery for a primary SGC in a tertiary referral center between 1990 and 2014. Immunohistochemical (IHC) staining for Trop-2 was performed and rated as negative, weak, moderate or high using a semiquantitative score. Additionally, representative cases were analyzed using MALDI-mass spectrometry (MS) imaging to confirm the IHC results. The cohort consisted of 114 tumors of the parotid gland (90.4%) and submandibular gland (9.6%). It mainly included mucoepidermoid, salivary duct and adenoid cystic carcinomas. In IHC samples, 44% showed high, 38% moderate and 10% weak expression rates of Trop-2. MALDI-MS imaging confirmed the presence of Trop-2 protein in 80% of the tested tumor samples. This is the first study to demonstrate that several types of SGC express Trop-2 with variable intensity. Since there are currently few systemic treatment options for advanced SGCs, Trop-2 represents a promising target for further clinical studies, for instance, with sacituzumab govitecan.

show abstract

Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)‑positive advanced salivary duct carcinoma: A case report

Cited by 10 publications

References 25 publications

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review

RANK and RANKL Expression in Salivary Gland Tumors

Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target

Contact Info

Product

Resources

About